(Q37973248)

26 August 2017

title

Treatment of neuromyelitis optica: an evidence based review (English)

1 reference

26 August 2017

0 references

1 reference

Douglas Sato

1

1 reference

26 August 2017

Dagoberto Callegaro

2

1 reference

26 August 2017

Marco Aurélio Lana-Peixoto

3

1 reference

26 August 2017

Kazuo Fujihara

4

1 reference

26 August 2017

Brazilian Committee for Treatment and Research in Multiple Sclerosis

5

1 reference

26 August 2017

publication date

1 January 2012

1 reference

Arquivos de Neuro-Psiquiatria

26 August 2017

published in

1 reference

26 August 2017

volume

70

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

59-66

1 reference

The clinical course of neuromyelitis optica (Devic's syndrome).

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Revised diagnostic criteria for neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Antibody to aquaporin-4 in the long-term course of neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Therapeutic plasma exchange: an update from the Canadian Apheresis Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Clinical applications of therapeutic apheresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Complications of plasma exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Intermittent plasmapheresis prevents recurrence in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

The rescue effect of plasma exchange for neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Neuromyelitis optica treatment: analysis of 36 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

An open label study of the effects of rituximab in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Immunosuppressive therapy is more effective than interferon in neuromyelitis optica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

A case of relapsing neuromyelitis optica treated with glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

Therapeutic Efficacy of Interferon β-1b in Japanese Patients with Optic-Spinal Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-282X2012000100012

10.1590/S0004-282X2012000100012

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference